Business Roundtable
Big Pharma's Wish List
Friday, October 31, 2008
9:45am - 11:00am
Pacific Heights
With the marked decline in R&D investment & touted increase in acquisition outlook, what is big Pharma looking for from the Biotech industry and what is the preferred mode of collaboration? A panel of senior pharma business development executives and franchise heads will address recent deal flow, pipeline needs and what's front of mind for collaborations in 2009.
With pre-panel introduction by Glen Giovannetti, Global Biotechnology Leader, Ernst & Young
Moderator
- TBA
Panelists
- F. Leslie Boyd, Jr, PhD, VP of Scientific Licensing, GlaxoSmithKline
- Ellen Lubman, Group Director of Strategic Transactions Group, Bristol-Myers Squibb
- Scott Morrison, Life Science Partner, Ernst & Young
- Yael Weiss, MD, PhD, Director of Licensing and External Research, Merck Research Laboratories, Merck & Co., Inc.
Who's Who
Glen Giovannetti Mr. Giovannetti is Ernst & Young's Global Biotechnology Leader based in Boston. He is a US CPA and has served as an auditor in the US and in Milan (Italy) for 22 years. Since 1992, he has been specializing in the biotech industry and has been involved in establishing Ernst & Young's Global Biotech Report "Beyond Borders" for several years.
Yael Weiss, MD, PhD Dr. Weiss completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Dr. Weiss joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Dr. Weiss joined Merck's Israeli subsidiary as medical director in the beginning of 2004 and this summer joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast.
Scott Morrison Mr. Morrison is a fourth generation San Franciscan, a U.C. Berkeley graduate, a Certified Public Accountant, and has provided business advisory and audit services to Bay Area technology companies since 1980. He co-authored E&Y's Biotech 2000 "Convergence," Biotech 99 "Bridging the Gap," and Biotech 98 "New Directions;" and served on the Advisory Council of the U.C. Entrepreneurs' Forum.
Mr. Morrison has extensive experience with both public and private financings including venture financings and initial and follow-on offerings (both debt and equity); has worked on over $5 billion dollars of M&A transactions and is considered a recognized expert in the M&A arena including both poolings and purchase transactions; and his clients include a large number of our local biotechnology companies.
Ellen Lubman Ellen Lubman is a Group Director in the new Strategic Transactions Group at Bristol-Myers Squibb. This group manages transactions for BMS, from Licensing and Business Development to M&A- as well as looks into novel strategic initiatives. Prior to BMS, Ellen worked with Celtic Pharma, L.P., a private equity fund which acquires direct ownership or controlling stakes in commercially attractive pharmaceutical products in the late stages of clinical and regulatory development while funding and actively managing these products through the last two to four years of clinical development. Ellen came to Celtic Pharma from a Business Development role with VIA Pharmaceuticals, a start-up cardiovascular disease biotechnology company incubated at Bay City Capital in San Francisco. During the heyday of the Human Genome Project, Ellen was a Biotechnology Equity Research Analyst at Robertson Stephens where she focused on in Genomics, Proteomics, Drug Discovery and Technology Platform companies, and developed research pieces on genetic Intellectual Property, Single Nucleotide Polymorphisms and other biotech